Ticker: RGNX

Regenxbio Inc. (NASDAQ: RGNX) surged 7.2% in premarket after the FDA accepted its BLA for RGX-121, a gene therapy for MPS II. With a target action date of Nov 9, 2025, this potential breakthrough could reshape treatment for Hunter syndrome.